• 1
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia: current status and investigational options. Science. 1990; 274: 824830.
  • 2
    Kelliher M, McLaughlin J, Witte O, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA. 1990; 87: 66496653.
  • 3
    Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340: 13301340.
  • 4
    Goldman JM, Melo JF. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med. 2003; 349: 14611464.
  • 5
    Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988; 61: 14411446.
  • 6
    Savage DG, Sazydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997; 99: 3035.
  • 7
    Vardiman J, Harris N, Brunning R. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 22922302.
  • 8
    Druker B, Tamura S, Buchduner E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561566.
  • 9
    Druker BJ. Update on imatinib therapy for chronic myeloid leukemia. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer principles and practice of oncology, 6th edition. Volume 16. Philadelphia: Lippincott Williams & Wilkins, 2002: 110.
  • 10
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of specific inhibitor of the BCR-ABL tyrosine in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med. 2001; 344: 10381042.
  • 11
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 10311037.
  • 12
    Kantarjian H, Sawyers CL, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 13
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood. 2002; 99: 19281937.
  • 14
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood. 2002; 99: 35303539.
  • 15
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 9941004.
  • 16
    Kantarjian H, O'Brien S, Cortes J, et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α regimens for early chronic phase. Cancer. 2003; 98: 14301437.
  • 17
    Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004; 10: 6875.
  • 18
    Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003; 98: 26362642.
  • 19
    Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002; 8: 21672176.
  • 20
    Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003; 9: 160166.
  • 21
    Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 2000; 95: 6266.
  • 22
    Paschka P, Muller M, Merx K, et al. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon-alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003; 17: 16871694.
  • 23
    Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 14231432.
  • 24
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 25
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 26
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972; 34: 187220.
  • 27
    Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003; 98: 11051113.
  • 28
    Huntly B, Guilhot F, Reid A, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood. 2003; 102: 22052212.
  • 29
    Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003; 17: 14481453.
  • 30
    National Marrow Donor Program. Disease and transplant outcome data, NMDP-facilitated transplant outcomes. National Marrow Donor Program, 2004. Available from URL: outcome data.html [accessed September 15, 2004].
  • 31
    Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399401.